BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17301646)

  • 1. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis.
    Sjöstedt S; Befrits R; Sylvan A; Harthon C; Jörgensen L; Carling L; Modin S; Stubberöd A; Toth E; Lind T
    Aliment Pharmacol Ther; 2005 Aug; 22(3):183-91. PubMed ID: 16091055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esomeprazole versus pantoprazole for healing erosive oesophagitis.
    Vcev A; Begić I; Ostojić R; Jurcić D; Bozić D; Soldo I; Gmajnić R; Kondza G; Khaznadar E; Mićunović N
    Coll Antropol; 2006 Sep; 30(3):519-22. PubMed ID: 17058517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2006; 74(3-4):145-54. PubMed ID: 17230024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2007; 75 Suppl 1():69-78. PubMed ID: 17489035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.
    Atug O; Giral A; Kalayci C; Dolar E; Isitan F; Oguz D; Ovunc O; Ozgur O; Soykan I; Simsek I; Unal S; Yenice N;
    Adv Ther; 2008 Jun; 25(6):552-66. PubMed ID: 18568450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.
    Bardhan KD; Achim A; Riddermann T; Pfaffenberger B
    Aliment Pharmacol Ther; 2007 Jun; 25(12):1461-9. PubMed ID: 17539986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients.
    Tulassay Z; Stolte M; Sjölund M; Engstrand L; Butruk E; Malfertheiner P; Dite P; Tchernev K; Wong BC; Gottlow M; Eklund S; Wrangstadh M; Nagy P
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):526-36. PubMed ID: 18467912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
    Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.